A method for screening recombinant proteins that inhibit the phagocytic function of macrophages on myelin proteins and a hydrogel formulation.
By screening and applying recombinant human hair keratin RK31 hydrogel formulation, the problem of regulating macrophage phagocytic function after spinal cord injury was solved, achieving precise repair of the spinal cord injury site and reduction of inflammatory response, and promoting neuronal regeneration.
Patent Information
- Application Number
- CN202510697899.5
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2025-05-27
- Publication Date
- 2026-11-17
- Estimated Expiration
- 2045-05-27
AI Technical Summary
Current treatments cannot precisely regulate the phagocytic function of macrophages in the area of spinal cord injury, resulting in a prolonged inflammatory response after spinal cord injury and inhibiting neuronal regeneration.
By screening out recombinant human hair keratin that can inhibit the phagocytic function of macrophages of myelin proteins, a hydrogel formulation was prepared, containing recombinant human hair keratin RK31 and photocurable hydrogel, for the repair of spinal cord injuries.
It significantly inhibits macrophage phagocytosis, reduces inflammatory response after spinal cord injury, promotes neuronal regeneration, and achieves efficient repair of spinal cord injury.
Smart Images

Figure CN120490507B_ABST
Abstract
Description
Technical Field
[0001] This invention belongs to the field of biomedical technology, specifically relating to a method for screening recombinant proteins that inhibit the phagocytic function of macrophages on myelin proteins and a hydrogel formulation. Background Technology
[0002] Spinal cord injury (SCI) is a highly disabling central nervous system disease that often leads to persistent accumulation of local myelin debris (MD). Macrophages, which are responsible for clearing it, often form foam cells due to excessive MD phagocytosis, which slows down the phagocytosis of apoptotic neutrophils, thereby inhibiting neuronal regeneration and prolonging the duration of the inflammatory response.
[0003] Previous studies have found that recombinant human hair keratin plays a role in regulating neuroinflammation and promoting nerve regeneration after spinal cord injury (SCI). However, current treatment methods have significant limitations in treating SCI, mainly because commonly used local intraperitoneal injections of modulators cannot precisely regulate the local spinal cord injury. Furthermore, there are currently no reports on the effect of recombinant human hair keratin on macrophage phagocytosis of spinal cord injury (MD), making it difficult to regulate the phagocytic function of macrophages in the injured area.
[0004] In conclusion, it is necessary to propose new strategies and improvements to address the shortcomings of existing technologies. Summary of the Invention
[0005] The purpose of this invention is to provide a method for screening recombinant keratin that inhibits the phagocytic function of macrophages and a hydrogel formulation containing such recombinant keratin, thereby partially solving or alleviating the above-mentioned deficiencies in the prior art. The specific technical solution adopted by this invention is as follows.
[0006] A first aspect of the present invention is to provide a method for screening recombinant keratin that can inhibit macrophage phagocytosis of MD.
[0007] A method for screening recombinant proteins that inhibit the phagocytic function of macrophages on myelin proteins, comprising the following steps: S01: Prepare various recombinant human hair keratin, and prepare the recombinant human hair keratin into a protein solution and co-culture it with macrophages in an environment rich in myelin; S02: Perform the first indicator test, which is the phagocytic rate of macrophages on myelin proteins; screen out recombinant human hair keratin species with a macrophage phagocytic rate of less than 20% on myelin proteins; S03: The recombinant human hair keratin species selected in S02 are subjected to a second indicator test, wherein the second indicator is the transcription level of foam cell-specific marker proteins; recombinant human hair keratin species that can significantly reduce foam cell-specific marker proteins are screened out; the foam cell-specific marker proteins include one or more of ABCA1, ABCG1, CD9, GPNMB, MMP9, OLR1, SPP1 and / or TREM2.
[0008] As a preferred embodiment, the foam cell-specific marker proteins include ABCA1, ABCG1, CD9, GPNMB, MMP9, OLR1, SPP1, and TREM2.
[0009] Furthermore, the screening method may also include a third indicator, which is lipid staining within macrophages; performing lipid staining on recombinant human hair keratin screened by SO2 within macrophages; and screening out recombinant human hair keratin species that reduce the lipid staining area within macrophages by about 2 / 3.
[0010] As a preferred embodiment, a method for screening recombinant proteins that inhibit the phagocytic function of macrophages on myelin proteins includes the following steps: S01: Prepare various recombinant human hair keratin, and prepare the recombinant human hair keratin into a protein solution and co-culture it with macrophages in an environment rich in myelin; S02: Perform the detection of the first and second indicators. The first indicator is the phagocytosis rate of macrophages on myelin proteins, and the second indicator is the lipid staining in macrophages. Screen out recombinant human hair keratin species that simultaneously meet the requirements of a macrophage phagocytosis rate of less than 20% on myelin proteins and a reduction of approximately 2 / 3 in the lipid staining area in macrophages. S03: The recombinant human hair keratin species selected in S02 are tested for a third indicator (verification). The third indicator is the transcription level of foam cell-specific marker proteins. The recombinant human hair keratin species that can significantly reduce foam cell-specific marker proteins are screened out. The foam cell-specific marker proteins include ABCA1, ABCG1, CD9, GPNMB, MMP9, OLR1, SPP1 and TREM2. Furthermore, the various recombinant human hair keratins described in S01 include RK86, RK85, RK84, RK83, RK82, RK81, RK40, RK39, RK38, RK37, RK36, RK35, RK34, RK33B, RK33A, RK32, and RK31.
[0011] Furthermore, the concentration of the protein solution prepared in S01 is 0.2 mg / mL.
[0012] Furthermore, the concentration of myelin in S01 is 10 mg / mL.
[0013] The recombinant human hair keratin obtained by the above screening method inhibits the phagocytic function of macrophages on myelin proteins. The recombinant human hair keratin is RK31, and its amino acid sequence is shown in SEQ ID NO.1.
[0014] Another aspect of the present invention is to provide a recombinant human hair keratin hydrogel formulation that can precisely repair local SCI damage.
[0015] A recombinant keratin hydrogel formulation for reducing inflammatory response after spinal cord injury, the recombinant keratin hydrogel formulation comprising recombinant human hair keratin RK31 and a photocurable hydrogel; the amino acid sequence of the recombinant human hair keratin RK31 is shown in SEQ ID NO.1; the photocurable hydrogel is methacrylamide gelatin.
[0016] Furthermore, the recombinant keratin hydrogel formulation has the effect of reducing the inflammatory response after spinal cord injury by inhibiting macrophages at the site of spinal cord injury from phagocytizing myelin proteins to form foam cells.
[0017] Furthermore, the recombinant keratin hydrogel formulation has a structure that couples to the irregular wound at the site of spinal cord injury.
[0018] Preferably, the volume ratio of the recombinant human hair keratin RK31 to the photocurable hydrogel is 2:1.
[0019] Furthermore, a photoinitiator is added to the photocurable hydrogel, wherein the photoinitiator is lithium phenyl (2,4,6-trimethylbenzoyl) phosphate.
[0020] Beneficial technical effects: (1) This invention first provides a method for screening functionalized recombinant human hair keratin based on the examination of macrophage phagocytosis of myelin. The method provided by this invention involves the detection of multiple indicators to screen recombinant human hair keratin that can significantly inhibit macrophage phagocytosis of myelin proteins; the detection indicators include the phagocytosis rate of macrophages of MD and / or the accumulation of intracellular lipids in macrophages in a MD-rich environment, as well as the transcription level of foam cell-specific marker proteins. The first two indicators can show from a relatively intuitive level whether a specific keratin has an inhibitory effect on macrophage phagocytosis of MD; the last indicator can accurately reflect whether a specific keratin inhibits the transcription level of foam cell-specific marker proteins, thereby screening recombinant human hair keratin that can significantly inhibit macrophage phagocytosis of myelin proteins for practical application. It is worth noting that this invention discloses for the first time the relationship between specific recombinant keratin subtypes regulating macrophage phenotypic changes and macrophage phenotypic changes and their phagocytic function of MD, providing a new approach for screening recombinant human hair keratin with specific functions.
[0021] (2) Secondly, based on the recombinant human hair keratin RK31 that was screened out and can significantly inhibit the phagocytic function of macrophages on myelin proteins, the present invention also provides a hydrogel preparation loaded with a high concentration of recombinant human hair keratin RK31. The hydrogel preparation can couple complex spinal cord injury wounds to achieve sustained release at the injury site and achieve efficient repair of spinal cord injury by controlling the inflammatory response. Attached Figure Description
[0022] To more clearly illustrate the technical solutions in the embodiments of the present invention or the prior art, the drawings used in the description of the embodiments or the prior art will be briefly introduced below. In all the drawings, similar elements or parts are generally identified by similar reference numerals. The elements or parts in the drawings are not necessarily drawn to scale. Obviously, the drawings described below are some embodiments of the present invention, and those skilled in the art can obtain other drawings based on these drawings without any creative effort.
[0023] Figure 1 This is an SDS-PAGE image of 17 recombinant human hair keratin synthesized in one embodiment of the present invention; Figure 2 This is a verification of the phagocytic MD function of macrophages by 17 recombinant human hair keratin synthesized in one embodiment of the present invention; Figure 3 This is a verification of the effect of 17 recombinant human hair keratin synthesized in one embodiment of the present invention on intracellular lipid accumulation in macrophages in a MD-rich environment; Figure 4This invention provides an example of how RK31 was used to verify the transcriptional level of maeker protein in foam cells of macrophages in a MD-rich environment. Figure 5 This invention is used to verify the effect of RK31 on the transcriptional level of macrophage MD phagocytic targets in one embodiment of the invention. Figure 6 This invention is used to verify the effect of macrophages on MD phagocytosis in the presence of an antagonist in one embodiment of the invention. Figure 7 This is one embodiment of the invention showing the effect of gradient-decreasing concentrations of RK31 on various indicators of macrophages in a MD-rich environment; Figure 8 This is a photocuring process of RK31-loaded hydrogel and a pore image under a scanning electron microscope (scale bar 300 μm) in one embodiment of the present invention. Figure 9 This is a Fourier transform infrared spectrum of a hydrogel loaded with RK31 in one embodiment of the present invention; Figure 10 This is for the mechanical property verification of the RK31-loaded hydrogel in one embodiment of the present invention; Figure 11 The footprint test (4 w and 8 w), BBB score (1 / 2 / 3 / 4 / 5 / 6 / 7 / 8 w), and ramp test (8 w) at different time points after implantation of RK31-loaded hydrogel into a rat SCI hemisection model are shown in one embodiment of the present invention. Figure 12 This is an example of foam cell accumulation at different time points (4 w and 8 w) after implantation of RK31-loaded hydrogel into a rat SCI hemisection model in one embodiment of the present invention. Figure 13 This is a diagram showing the local nerve regeneration status 8 weeks after implantation of RK31-loaded hydrogel into a rat SCI hemisection model in one embodiment of the present invention. Figure 14 This is the result of differential expression of local inflammatory factors 8 weeks after implantation of RK31-loaded hydrogel into a rat SCI hemisection model in one embodiment of the present invention. Detailed Implementation
[0024] To make the objectives, technical solutions, and advantages of the embodiments of the present invention clearer, the technical solutions of the embodiments of the present invention will be clearly and completely described below with reference to the accompanying drawings. Obviously, the described embodiments are only some, not all, of the embodiments of the present invention. All other embodiments obtained by those skilled in the art based on the embodiments of the present invention without creative effort are within the scope of protection of the present invention.
[0025] In this document, "and / or" includes any and all combinations of one or more of the listed related items.
[0026] In this article, "multiple" means two or more, that is, it includes two, three, four, five, etc.
[0027] As used in this specification, the term "about" typically means + / -5% of the value, more typically + / -4% of the value, more typically + / -3% of the value, more typically + / -2% of the value, even more typically + / -1% of the value, and even more typically + / -0.5% of the value.
[0028] In this specification, certain embodiments may be disclosed in a range-bound format. It should be understood that this "range-bound" description is merely for convenience and brevity and should not be construed as a rigid limitation on the disclosed range. Therefore, the description of a range should be considered as having specifically disclosed all possible subranges and the individual numerical values within that range. For example, a description of the range 1-6 should be considered as having specifically disclosed subranges such as from 1 to 3, from 1 to 4, from 1 to 5, from 2 to 4, from 2 to 6, from 3 to 6, etc., and the individual numbers within that range, such as 1, 2, 3, 4, 5, and 6. This rule applies regardless of the breadth of the range.
[0029] Example 1 In this embodiment, 17 keratin subtypes were recombinantly expressed using a prokaryotic recombinant expression system. After verifying the successful expression, they were added to a macrophage culture environment rich in MD to further explore the effects of different keratin subtypes on the macrophage's phagocytic function of MD and whether they would affect foam cell generation.
[0030] First, in this embodiment, 17 recombinant human hair keratin isotypes were synthesized based on a prokaryotic recombinant expression system, namely RK86, RK85, RK84, RK83, RK82, RK81, RK40, RK39, RK38, RK37, RK36, RK35, RK34, RK33B, RK33A, RK32, and RK31. Their SDS-PAGE images are shown below. Figure 1 .
[0031] Furthermore, the effects of the aforementioned 17 recombinant human hair keratin derivatives on the phagocytic function of macrophages in a MD-rich environment were investigated. The methods were as follows: Macrophages were co-cultured with the 17 recombinant human hair keratin derivatives at a concentration of 0.20 mg / mL in a MD-rich environment (MD concentration was set at 10 mg / mL) for 24 h. The phagocytic rate of macrophages on MD was detected by flow cytometry. (See figure below). Figure 2 The results showed that the RK31 group had the lowest percentage of MD.
[0032] Furthermore, the effects of the aforementioned 17 recombinant human hair keratins on intracellular lipid accumulation in macrophages in a MD-rich environment were investigated, see [link to study]. Figure 3 . Figure 3 The left image shows Nile Red staining, which can mark lipid droplets and cell membranes and help determine the amount of lipid droplets in cells. Figure 3 The right image shows Oil Red O staining to label lipid droplets within cells. Both images show that the RK31 group had the smallest lipid droplet area, demonstrating that recombinant protein RK31 can effectively reduce lipid accumulation within macrophages.
[0033] Based on the above experimental results, the effect of RK31 on the transcriptional level of maeker protein in foam cells of macrophages in a MD-rich environment was further investigated, see [link to study]. Figure 4 The results showed that most protein markers were reduced in the RK31+MD group, proving that RK31 can effectively inhibit macrophage phagocytosis of MD.
[0034] Example 2 This embodiment investigates the mechanism by which RK31 reduces excessive phagocytosis of macrophages by macrophages and reduces foam cell formation by adding antagonist components and using gradient concentrations of RK31.
[0035] The antagonist used in this embodiment was LRPAP1 protein at a concentration of 2 μg / mL; the co-incubation time with macrophages, MD, and RK31 was 2 h. The initial concentration of RK31 protein was set at 0.20 mg / mL, and the concentration gradient was set at 0.20 mg / mL, 0.13 mg / mL, 0.07 mg / mL, and 0. Subsequently, flow cytometry was used to detect the inhibitory effect of LRPAP1 protein on macrophage phagocytosis of MD.
[0036] The experimental results are shown in Figures 5-7 . Figure 5 The RT-qPCR results showed changes in gene transcription levels, with RK31 significantly inhibiting the transcription of the macrophage LRP1 gene, demonstrating that RK31 affects the transcription level of macrophage MD phagocytic targets. Figure 6 The results showed that LRP1 antagonists significantly inhibited macrophage phagocytosis of MD. Figure 7 The results showed that gradually decreasing concentrations of RK31 restored LRP1 expression, phagocytic activity against MD, and intracellular lipid accumulation in macrophages in a MD-rich environment, while gradually losing its inhibitory effect on foam cell formation.
[0037] Example 3 This embodiment provides a hydrogel formulation containing recombinant keratin RK31 and functional verification of the hydrogel formulation.
[0038] First, a method for preparing a hydrogel formulation containing recombinant keratin RK31 is provided: 20 μL of RK31 aqueous solution (10 mg / mL), 250 μL of GelMA solution (20% w / v), and 630 μL of ddH2O are mixed, and 100 μL of LAP (1.5% w / v) is added. The mixture is then thoroughly mixed and cured under ultraviolet light to obtain a hydrogel loaded with a low concentration of recombinant keratin RK31, labeled Gel-RK31(L). Alternatively, 500 μL of RK31 aqueous solution (10 mg / mL), 250 μL of GelMA solution (20% w / v), and 150 μL of ddH2O are mixed, and 100 μL of LAP (1.5% w / v) is added. The mixture is then thoroughly mixed and cured under ultraviolet light to obtain a hydrogel loaded with a low concentration of recombinant keratin RK31, labeled Gel-RK31(H). The amino acid sequence of the recombinant keratin RK31 used in this embodiment is as described in SEQ ID NO. 1.
[0039] Table 1 The hydrogel prepared above and loaded with recombinant keratin RK31 was validated, and the results are shown in the figure. Figures 8-10 The results showed that the hydrogel loaded with recombinant keratin RK31 had a pore size of 300 μm. The larger pore size facilitated substance exchange and cell colonization within the hydrogel. Fourier transform infrared spectroscopy revealed a characteristic peak: amide A (2800-4000 cm⁻¹). -1 ), Amide I band (1600 - 1700 cm) -1 Amide II band (1480 - 1580 cm) -1 Amide III band (1220 - 1330 cm) -1 ), Amide B band (3069 cm) -1 The mechanical properties of the hydrogel loaded with recombinant keratin RK31 were tested, showing a swelling rate of 1500% after 24 hours; a degradation rate of 50% after 4 weeks; and a compressive modulus of 6 kPa. The good swelling rate allows for coupling of the hydrogel with irregular wounds.
[0040] The above results indicate that the hydrogel loaded with recombinant keratin RK31 has excellent swelling properties and can couple irregular wounds of spinal cord injury in a short time to achieve sustained release and efficient and precise repair. In addition, the prepared hybrid hydrogel retains the excellent properties of GelMA hydrogel and the chemical structural characteristics of RK31 to the maximum extent, and does not significantly damage the mechanical properties of GelMA.
[0041] Example 4 This embodiment further verifies the effect of the hydrogel loaded with recombinant keratin RK31 prepared in Example 3 in an animal model of injury.
[0042] (1) RK31-GelMA hydrogel was implanted into a rat spinal cord injury hemisection model and the recovery of rat motor function was verified.
[0043] Experimental Methods: The BBB assessment method was used to evaluate the recovery of motor function in the affected hind limb of rats in an open environment. For 8 weeks post-surgery, two independent researchers systematically assessed and recorded scores weekly.
[0044] Footprint experiment: At 4 and 8 weeks post-SCI, rats were placed in a specially designed tunnel with a dark chamber at the end to train them to move within the tunnel. White paper was laid on the tunnel floor to track the rats' footprints. For ease of tracking, the insteps of each rat's hind feet were evenly coated with red washable pigment, while the soles were coated with blue washable pigment. Rats were trained to move from the beginning of the tunnel to the dark chamber before the experiment to collect their footprints, which were then photographed for analysis.
[0045] Inclined Plane Test: Eight weeks after SCI, rats were placed on an inclined plank covered with a rubber pad. Each rat's body longitudinal axis was parallel to the inclined plank, with its head facing the elevated end. The maximum angle the rat could maintain on the inclined plank for 5 seconds was recorded, starting from 0° and gradually increasing in 2° increments. Five measurements were performed on each rat, and the average value was calculated and recorded. Results are shown below. Figure 11 .
[0046] Table 2 BBB Score Results (2) At 4 and 8 weeks after spinal cord injury, the effect of hydrogel implantation on foam cell generation at the injury site was investigated.
[0047] Experimental Methods: Rats were anesthetized by intraperitoneal injection of pentobarbital (30 mg / kg) and fixed to the operating table in a supine position. The xiphoid process was used as a landmark, and the thorax was gradually opened along the lower edge of the ribs using a sharp scalpel to expose the heart, lungs, and liver. Care was taken not to damage the heart or lung lobes during the procedure, and to avoid touching major blood vessels in the chest to prevent rat death. The infusion needle was slowly inserted into the heart through the left ventricle, and then secured with forceps to prevent slippage. A small incision was carefully made at the right atrial appendage, and pre-cooled sterile saline was slowly infused into the heart, initially slowly and then rapidly, until the fluid flowing from the right atrial appendage became clear. After the saline infusion was complete, pre-cooled 4% paraformaldehyde was continued to be infused, with each rat receiving at least 200 mL of 4% paraformaldehyde. Successful infusion was indicated by generalized limb twitching. The incision site was exposed layer by layer using a sharp scalpel, and a 2-3 cm section of the spine was harvested from the lesion point. The spinal cord tissue was then carefully removed from ice using forceps and bone forceps, and photographed according to the group. The obtained spinal cord tissue was fixed in 4% paraformaldehyde for 6 hours, then cleaned and successively immersed in 10%, 20%, and 30% sucrose solutions for dehydration. After complete settling, the surface moisture was blotted dry with filter paper, then embedded in OCT embedding medium and frozen, and stored at -80°C. The cryostat was set to -25°C, and the embedded tissue was fixed on the stage of the cryostat for a short thaw before sectioning. The section thickness was set to 25 μm (Oil Red O staining), and longitudinal continuous sections parallel to the long axis of the spinal cord were prepared. The tissue sections were mounted on high-adhesion slides and observed under an optical microscope to check tissue integrity. More intact sections were marked with information, and after the OCT embedding medium thawed, they were sealed and stored at -20°C. The processed sections were then immersed in 60% isopropanol for 10 minutes. Isopropanol was then removed, and the sample was immersed in the prepared Oil Red O staining working solution and incubated at room temperature in the dark for 15 min.
[0048] After incubation, the staining solution was aspirated, and the samples were washed three times with PBS for 5 minutes each time. 60% isopropanol was added and incubated for another 30 seconds. After removing the isopropanol, the samples were washed again. The samples were mounted with glycerol gelatin and observed and photographed under an optical microscope for analysis. Results are shown below. Figure 12 .
[0049] (3) Eight weeks after spinal cord injury, we investigated the effect of hydrogel implantation on nerve regeneration and repair at the injury site.
[0050] Experimental Methods: Frozen sections of spinal cord were removed from a -20°C freezer and allowed to air dry thoroughly at room temperature. They were then dried in a 65°C oven for 1 hour, and then slowly cooled at room temperature. Next, the sections were immersed in PBS buffer and rinsed for 5 minutes, repeated three times (the treated sections can be used for Oil Red O staining and LFB staining). Afterward, they were immersed in Tris-EDTA antigen retrieval solution and microwaved on medium for 8 minutes and then on low for 12 minutes. The sections were then slowly cooled at room temperature. The treated sections were ready for immunofluorescence staining. For immunohistochemical staining, 3% H2O2 solution was added to the sections, and the sections were incubated in a humidified chamber at room temperature for 10 minutes, followed by rinsing with PBS for 5 minutes, repeated three times. After processing, the tissue sections were marked with an immunohistochemical pen to define the areas to be stained. Permeation buffer (containing 0.3% Triton X-100) was then added for 10 min for tissue permeation. After washing, the sections were blocked in a humidified chamber at room temperature for 1 h using tissue blocking buffer containing 5% BSA. The diluted NEUN / GFAP antibody was then added to the areas to be stained after the blocking buffer was removed, just enough to slightly submerge them. The sections were then placed in a humidified chamber and incubated overnight at 4°C. The chamber was then removed and allowed to warm to room temperature for 30 min. The primary antibody was slowly aspirated, and the sections were gently rinsed three times with PBST buffer for 15 min each time. The diluted fluorescently labeled secondary antibody was then applied to the tissue, and the sections were incubated in a humidified chamber at room temperature in the dark for 1 h. The sections were then gently rinsed three times with PBST buffer in the dark for 15 min each time. Finally, an appropriate amount of anti-fluorescent, anti-quenched DAPI mounting solution was added to the cleaned sections, and air bubbles were slowly removed using a coverslip before mounting. The mounted sections were scanned under a fluorescence microscope to acquire images for subsequent analysis. Results are shown below. Figure 13 The damaged tissue was divided into three distinct regions: the injury zone (IA: a region composed of newly formed tissue), the scar zone (SA: a region composed of local glial scars after injury), and the degenerative zone (DA: a region retaining a large number of necrotic cells and MD). As shown in the figure, Gel-RK31(H) exhibits a significant repair effect on the injury zone, with a significantly higher modification effect than Gel-RK31(L).
[0051] Furthermore, the differential expression levels of local inflammatory factors at 8 weeks after implantation of RK31-loaded hydrogel into a rat SCI hemisection model were analyzed, including changes in the pro-inflammatory polarization phenotype (CD86 and TNF-α) and anti-inflammatory polarization phenotype (CD206 and Arg-1) of macrophages. (See attached image). Figure 14 In the figure, I represents control, II represents Gel, III represents Gel-RK31(L), and IV represents Gel-RK31(H). The results showed that Gel-RK31(H) could significantly inhibit the expression level of the pro-inflammatory polarization phenotype of macrophages after spinal cord injury and promote the expression level of the anti-inflammatory polarization phenotype, thereby alleviating the inflammation level after spinal cord injury.
[0052] It should be noted that, in this document, the terms "comprising," "including," or any other variations thereof are intended to cover non-exclusive inclusion, such that a process, method, article, or apparatus that comprises a list of elements includes not only those elements but also other elements not expressly listed, or elements inherent to such a process, method, article, or apparatus. Unless otherwise specified, an element defined by the phrase "comprising one..." does not exclude the presence of other identical elements in the process, method, article, or apparatus that includes that element.
[0053] The embodiments of the present invention have been described above with reference to the accompanying drawings. However, the present invention is not limited to the specific embodiments described above. The specific embodiments described above are merely illustrative and not restrictive. Those skilled in the art can make many other forms under the guidance of the present invention without departing from the spirit and scope of the claims. All of these forms are within the protection scope of the present invention.
Claims
1. The use of a hydrogel formulation containing recombinant keratin in the preparation of a medicament for reducing inflammation following spinal cord injury, characterized in that, The hydrogel formulation containing recombinant keratin comprises recombinant human hair keratin RK31 and a photocurable hydrogel; the amino acid sequence of the recombinant human hair keratin RK31 is shown in SEQ ID NO.1; the photocurable hydrogel is methacrylamide gelatin; the hydrogel formulation containing recombinant keratin has the effect of reducing the inflammatory response after spinal cord injury by inhibiting macrophages at the site of spinal cord injury from phagocytizing myelin proteins to form foam cells.
2. The application as described in claim 1, characterized in that, The hydrogel formulation containing recombinant keratin has a structure that couples to the irregular wound at the site of spinal cord injury.
3. The application as described in claim 1, characterized in that, The volume ratio of the recombinant human hair keratin RK31 to the photocurable hydrogel is 2:
1.
4. The application as described in claim 3, characterized in that, A photoinitiator is added to the photocurable hydrogel, and the photoinitiator is lithium phenyl (2,4,6-trimethylbenzoyl) phosphate.
Citation Information
Patent Citations
Joint treatment method for slowing down inflammatory reaction mediated by microglial cells / macrophages after spinal cord injury
CN110404078A
Recombinant keratin injectable gel and preparation method thereof
CN117442780A
